CoChat

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Nelson, Mark, Arastéh, Keikawus, Clotet, Bonaventura, Cooper, David A, Henry, Keith, Katlama, Christine, Lalezari, Jacob P, Lazzarin, Adriano, Montaner, Julio S. G, O'Hearn, Mary, Piliero, Peter J, Reynes, Jacques, Trottier, Benoit, Walmsley, Sharon L, Cohen, Calvin, Eron, Joseph J, Kuritzkes, Daniel R, Lange, Joep, Stellbrink, Hans-Jürgen, Delfraissy, Jean-François, Buss, Neil E, Donatacci, Lucille, Wat, Cynthia, Smiley, Lynn, Wilkinson, Martin, Valentine, Adeline, Guimaraes, Denise, DeMasi, Ralph, Chung, Jain, Salgo, Miklos P · 2005 · JAIDS Journal of Acquired Immune Deficiency Syndromes
Cited by 153

The DOI matches its Crossref record.

Abstract

BACKGROUND: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB alone (n = 334) in treatment-experienced HIV-1-infected patients. METHODS: The primary objective at week 48 was to investigate durability of efficacy, as measured by the percentage of patients maintaining their week 24 response or improving. Efficacy analyses used the intent-to-treat population. RESULTS: A total of 73.7% of patients randomized to the enfuvirtide group remained on treatment through week 48 versus 21.3% originally randomized to the control group. At week 48, a higher proportion of week 24 responders maintained their response or were new responders in the enfuvirtide group than in the control group in each responder category: HIV-1 RNA level > or =1.0 log(10) change from baseline, <400 copies/mL and <50 copies/mL (37.4%, 30.4%, and 18.3% in the enfuvirtide group vs. 17.1%, 12.0%, and 7.8% in the control group, respectively; P < 0.0001 for all comparisons). CD4 cell count increases from baseline were twice as great in the enfuvirtide group as in the control group. CONCLUSION: These data demonstrate durable efficacy of enfuvirtide plus OB over 48 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.qai.0000185314.56556.c3

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 153

Metadata

Authors
Nelson, M., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O'Hearn, M., Piliero, P. J., Reynes, J., Trottier, B., Walmsley, S. L., Cohen, C., Eron, J. J., Kuritzkes, D. R., Lange, J., Stellbrink, H.-J., Delfraissy, J.-F., Buss, N. E., Donatacci, L., Wat, C., Smiley, L., Wilkinson, M., Valentine, A., Guimaraes, D., DeMasi, R., Chung, J., & Salgo, M. P.
Venue
JAIDS Journal of Acquired Immune Deficiency Syndromes
Published
2005-12-01
Volume
40
Issue
4
Pages
404-412
ISSN
1525-4135 (ISSN-L)
OpenAlex
W2312642584
Cited by
153
References
0
FWCI
13.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. https://app.cochat.ai/papers/10.1097/01.qai.0000185314.56556.c3
The paper
Nelson, M., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O'Hearn, M., Piliero, P. J., Reynes, J., Trottier, B., Walmsley, S. L., Cohen, C., Eron, J. J., Kuritzkes, D. R., Lange, J., Stellbrink, H.-J., . . . Salgo, M. P. (2005). Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/01.qai.0000185314.56556.c3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.